Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes.

[1]  S. Rosenberg,et al.  Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.

[2]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[3]  S. Rosenberg,et al.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes , 1991, The Journal of experimental medicine.

[4]  J. Cohen,et al.  Optimal collection of blood samples for the measurement of tumor necrosis factor alpha. , 1990, Cytokine.

[5]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[6]  C. Smith,et al.  A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. , 1990, Science.

[7]  G. Wong,et al.  Molecular cloning and expression of a receptor for human tumor necrosis factor , 1990, Cell.

[8]  Miller Ad,et al.  Improved Retroviral Vectors for Gene Transfer and Expression , 1989 .

[9]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[10]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Pfizenmaier,et al.  Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. , 1989, European journal of cancer & clinical oncology.

[12]  D. Kufe,et al.  Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. , 1988, Journal of the National Cancer Institute.

[13]  R. Kurzrock,et al.  A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Kufe,et al.  Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Tavernier,et al.  EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER , 1987, The Lancet.

[16]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[17]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[18]  A. Asher,et al.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.

[19]  W. Laird,et al.  Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. , 1986, Cancer research.

[20]  J. Strickler,et al.  Molecular cloning of the complementary DNA for human tumor necrosis factor. , 1985, Science.

[21]  A. Sakurai,et al.  Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice , 1984, International journal of cancer.

[22]  L. Old,et al.  Partial purification of a serum factor that causes necrosis of tumors. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.